Who are we?
Manufacturer of custom-made oral devices
Summary
Founded by a dental surgeon, ONIRIS is a 100% French company holding the title of a Young Innovative Company and whose shareholders are patients and doctors.
It all started with a simple observation: In France, 80% of the population suffering from snoring or sleep apnoea is not treated even though the consequences for the patient and society are multiple and sometimes serious. Several million people in France suffer from these pathologies without finding any solutions. Why? Because the existing therapeutic solutions were too restrictive, expensive, complex or simply ineffective.
Since 2008, our laboratory has been developing innovative mandibular advancement devices to effectively treat sleep disorders, particularly snoring and obstructive sleep apnoea.
More than 200,000 patients have been treated thanks to the solutions developed by ONIRIS.
Our mission statement
Enabling the greatest number of patients to have access to clinically approved therapeutic solutions offering the best compromise in terms of effectiveness, comfort, simplicity and cost.
Research and scientific advice
We place great importance on the research and development of new devices with a constant concern for comfort, effectiveness and reliability. We thus uniquely invest in innovative research & development and clinical validation programmes.
Our Research & Development programmes are determined and monitored by a scientific committee made up of recognised medical experts in the field of Sleep, Dentistry and Biostatistics.
Our innovative treatment solutions have won awards from research programmes such as EIT Health, Innov’Up and Futur en Seine and are supported by institutional partners such as the Ile de France Region and the Banque Publique d’Investissement (BPI) [French Public Investment Bank].
The clinical studies conducted on our innovative devices have involved more than 500 patients and dozens of doctors and dentists in offices and hospitals. Their results have been published in recognised international scientific journals and we communicate them transparently.
These studies provide the public and healthcare professionals with innovative treatments whose effectiveness and comfort are proven by objective, independent and reliable data.
They are also recognised by many journalists and specialised media.
International development
Since 2015 ONIRIS has initiated its international development and is now present in many countries in Europe and around the world.
The approval from the American drug agency (Federal Drug Administration, FDA) in 2016 and the Brazilian health agency (ANVISA) in 2019 means that distribution on the American continent is now possible.
Say goodbye to snoring!
Oniris® oral device
- Unique comfort to sleep peacefully
- Unmatched clinical effectiveness
- Secure online payment
A complete range of oral devices to meet your needs
| ONIRIS | ONIRIS Pro | Tali | |
|---|---|---|---|
| Freedom of movement | |||
| Millimetre-adjustment of the advancement | |||
| Custom-made impression | |||
| Clinically approved for snoring | |||
| Clinically approved for sleep apnoea | |||
| Approved by the French National Authority for Health | |||
| Developed by a trained dentist | |||
| Custom-made | |||
| Waiting time | 24-48 hours | 30 days | 3 to 9 months |
| Average lifespan | 12 to 24 months | 12 to 24 months | 5 years |